You are here: Home » PTI Stories » National » News
Business Standard

AstraZeneca receives nod to import, market cancer drug

Press Trust of India  |  New Delhi 

Pharma today said it has received import and market permission from the of (DCGI) for (Tagrisso) tablets, prescribed as first-line treatment for certain kinds of

Pharma said approval has been granted for the product in the strengths of 40 mg and 80 mg.

"The receipt of this permission paves way for the launch of in for first-line treatment. is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer," the company said in a BSE filing.

Pharma said in 2017, Osimertinib was granted 'Breakthrough Therapy' status and 'Priority Review' designations by the USFDA in first line treatment setting.

"Osimertinib is a patented product of AstraZeneca group," the company said.

is the leading cause of related mortality worldwide and amongst males in India with 5-year survival rates as dismal as 3.7 per cent in the country, it added.

Shares of were trading 0.43 per cent higher at Rs 1,750.95 apiece on BSE.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Thu, August 09 2018. 11:55 IST